Jubilant Pharmova Limited (JUBLPHARMA.BO)
INR 881.1
(-0.37%)
INR 881.1
(-0.37%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 14.45 Billion INR | -61.63% |
| 2022 | 37.66 Billion INR | 9.25% |
| 2021 | 34.47 Billion INR | 11.51% |
| 2020 | 30.91 Billion INR | 3.53% |
| 2019 | 29.86 Billion INR | -21.29% |
| 2018 | 37.93 Billion INR | 19.53% |
| 2017 | 31.73 Billion INR | 30.08% |
| 2016 | 24.39 Billion INR | 4.53% |
| 2015 | 23.34 Billion INR | -4.94% |
| 2014 | 24.55 Billion INR | 6.45% |
| 2013 | 23.06 Billion INR | 13.6% |
| 2012 | 20.3 Billion INR | 2.84% |
| 2011 | 19.74 Billion INR | 65.28% |
| 2010 | 11.94 Billion INR | -30.42% |
| 2009 | 17.16 Billion INR | 10533.7% |
| 2008 | -164.56 Million INR | -101.98% |
| 2007 | 8.29 Billion INR | 53.66% |
| 2006 | 5.39 Billion INR | 11.72% |
| 2005 | 4.83 Billion INR | 2146.86% |
| 2004 | 214.99 Million INR | -92.59% |
| 2003 | 2.9 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 9.89 Billion INR | -25.41% |
| 2024 Q1 | 4.6 Billion INR | 13.86% |
| 2023 FY | 14.45 Billion INR | -61.63% |
| 2023 Q4 | 4.04 Billion INR | -59.76% |
| 2023 Q2 | 9.64 Billion INR | -0.24% |
| 2023 Q1 | 9.66 Billion INR | 16.36% |
| 2023 Q3 | 10.05 Billion INR | 4.32% |
| 2022 Q3 | 10.03 Billion INR | 2.73% |
| 2022 Q4 | 8.3 Billion INR | -17.23% |
| 2022 FY | 37.66 Billion INR | 9.25% |
| 2022 Q1 | 9.55 Billion INR | 58.21% |
| 2022 Q2 | 9.76 Billion INR | 2.21% |
| 2021 Q1 | 9.65 Billion INR | 64.88% |
| 2021 FY | 34.47 Billion INR | 11.51% |
| 2021 Q2 | 9.54 Billion INR | -1.13% |
| 2021 Q3 | 9.23 Billion INR | -3.3% |
| 2021 Q4 | 6.04 Billion INR | -34.57% |
| 2020 Q2 | 8.37 Billion INR | 7.46% |
| 2020 Q1 | 7.79 Billion INR | 4.8% |
| 2020 Q3 | 8.88 Billion INR | 6.03% |
| 2020 Q4 | 5.85 Billion INR | -34.08% |
| 2020 FY | 30.91 Billion INR | 3.53% |
| 2019 Q4 | 7.44 Billion INR | -8.2% |
| 2019 Q2 | 11.11 Billion INR | 4.32% |
| 2019 Q1 | 10.65 Billion INR | 32.68% |
| 2019 Q3 | 8.1 Billion INR | -27.1% |
| 2019 FY | 29.86 Billion INR | -21.29% |
| 2018 Q4 | 8.03 Billion INR | -25.8% |
| 2018 Q3 | 10.82 Billion INR | 7.41% |
| 2018 Q2 | 10.07 Billion INR | 11.91% |
| 2018 FY | 37.93 Billion INR | 19.53% |
| 2018 Q1 | 9 Billion INR | -14.8% |
| 2017 Q4 | 10.56 Billion INR | 14.92% |
| 2017 Q3 | 9.19 Billion INR | 16.93% |
| 2017 Q2 | 7.86 Billion INR | 14.04% |
| 2017 FY | 31.73 Billion INR | 30.08% |
| 2017 Q1 | 6.89 Billion INR | -7.49% |
| 2016 Q2 | 6.61 Billion INR | 0.47% |
| 2016 Q1 | 6.58 Billion INR | -12.18% |
| 2016 FY | 24.39 Billion INR | 4.53% |
| 2016 Q3 | 7.09 Billion INR | 7.19% |
| 2016 Q4 | 7.45 Billion INR | 5.09% |
| 2015 FY | 23.34 Billion INR | -4.94% |
| 2015 Q4 | 7.5 Billion INR | 15.23% |
| 2015 Q3 | 6.51 Billion INR | -2.71% |
| 2015 Q2 | 6.69 Billion INR | 2.94% |
| 2015 Q1 | 6.5 Billion INR | 75.55% |
| 2014 Q4 | 3.7 Billion INR | -47.93% |
| 2014 FY | 24.55 Billion INR | 6.45% |
| 2014 Q1 | 6.77 Billion INR | 79.43% |
| 2014 Q2 | 6.96 Billion INR | 2.85% |
| 2014 Q3 | 7.11 Billion INR | 2.08% |
| 2013 Q4 | 3.77 Billion INR | -43.42% |
| 2013 FY | 23.06 Billion INR | 13.6% |
| 2013 Q2 | 6.61 Billion INR | 9.92% |
| 2013 Q1 | 6.01 Billion INR | -0.03% |
| 2013 Q3 | 6.67 Billion INR | 0.84% |
| 2012 Q1 | 4.62 Billion INR | 744.23% |
| 2012 Q3 | 5.57 Billion INR | 1.48% |
| 2012 FY | 20.3 Billion INR | 2.84% |
| 2012 Q2 | 5.49 Billion INR | 18.84% |
| 2012 Q4 | 6.02 Billion INR | 8.01% |
| 2011 Q4 | -717.46 Million INR | -113.33% |
| 2011 Q3 | 5.38 Billion INR | 0.0% |
| 2011 FY | 19.74 Billion INR | 65.28% |
| 2010 FY | 11.94 Billion INR | -30.42% |
| 2009 FY | 17.16 Billion INR | 10533.7% |
| 2008 FY | -164.56 Million INR | -101.98% |
| 2007 FY | 8.29 Billion INR | 53.66% |
| 2006 FY | 5.39 Billion INR | 11.72% |
| 2005 FY | 4.83 Billion INR | 2146.86% |
| 2004 FY | 214.99 Million INR | -92.59% |
| 2003 FY | 2.9 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 8.921% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 63.161% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | -24.168% |
| Granules India Limited | 7.18 Billion INR | -101.243% |
| Indoco Remedies Limited | 4.74 Billion INR | -204.373% |
| Achyut Healthcare Limited | 1.6 Million INR | -898221.939% |
| Ajanta Pharma Limited | 30.46 Billion INR | 52.552% |
| Alkem Laboratories Limited | 32.83 Billion INR | 55.98% |
| Alpa Laboratories Limited | 156.14 Million INR | -9156.662% |
| Brooks Laboratories Limited | 51.18 Million INR | -28141.501% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -455.838% |
| Bajaj HealthCare Limited | 985.34 Million INR | -1366.897% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -918.445% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 84.925% |
| Eris Lifesciences Limited | 4.94 Billion INR | -192.417% |
| FDC Limited | 5.34 Billion INR | -170.243% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 78.607% |
| Gufic Biosciences Limited | 1.07 Billion INR | -1241.176% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -580.45% |
| Ipca Laboratories Limited | 13.91 Billion INR | -3.874% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -1768.866% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -31215.539% |
| Lasa Supergenerics Limited | 291.17 Million INR | -4864.042% |
| Laurus Labs Limited | 3.01 Billion INR | -380.072% |
| Lupin Limited | 95.67 Billion INR | 84.892% |
| Mankind Pharma Limited | 23.15 Billion INR | 37.571% |
| Medicamen Biotech Limited | 335.16 Million INR | -4212.477% |
| Medico Remedies Limited | 161.84 Million INR | -8830.822% |
| Megasoft Limited | 49.52 Million INR | -29083.493% |
| NATCO Pharma Limited | 10.05 Billion INR | -43.707% |
| Piramal Pharma Limited | 19.91 Billion INR | 27.418% |
| RPG Life Sciences Limited | 1.63 Billion INR | -783.766% |
| Sigachi Industries Limited | 579.88 Million INR | -2392.555% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 90.625% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -930.376% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -1433.745% |
| Unichem Laboratories Limited | 6.72 Billion INR | -114.902% |
| Wanbury Limited | 1.16 Billion INR | -1145.04% |
| Windlas Biotech Limited | 1 Billion INR | -1336.051% |
| ZIM Laboratories Limited | 1.01 Billion INR | -1326.769% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 66.522% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -369.774% |
| Divi's Laboratories Limited | 14.17 Billion INR | -2.004% |
| Hester Biosciences Limited | 908.84 Million INR | -1490.379% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -382.54% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -1215.21% |
| Bal Pharma Limited | 389.89 Million INR | -3607.199% |
| Strides Pharma Science Limited | 9.16 Billion INR | -57.755% |
| Venus Remedies Limited | 1.91 Billion INR | -654.272% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -370.141% |
| Nectar Lifesciences Limited | 625.55 Million INR | -2210.607% |
| Shilpa Medicare Limited | 2.18 Billion INR | -562.848% |
| Aarti Drugs Limited | 1.16 Billion INR | -1138.052% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -1215.435% |
| Suven Life Sciences Limited | 109.75 Million INR | -13069.932% |
| Ind-Swift Limited | 946.56 Million INR | -1426.992% |
| Valiant Laboratories Limited | 36.28 Million INR | -39730.252% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | -71.722% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | -215.61% |
| Themis Medicare Limited | 782.85 Million INR | -1746.319% |
| Hikal Limited | 2.48 Billion INR | -481.336% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 32.528% |
| Sequent Scientific Limited | 2.9 Billion INR | -398.103% |
| Novartis India Limited | 470.1 Million INR | -2974.665% |
| Wockhardt Limited | 6.4 Billion INR | -125.844% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -89068.837% |
| Neuland Laboratories Limited | 2.92 Billion INR | -393.353% |
| Morepen Laboratories Limited | 1.98 Billion INR | -627.264% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -3404.62% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -2037.701% |